Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 26;13:1007429. doi: 10.3389/fphar.2022.1007429

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 He, Liang, Huang, Jiang, Liu, Sun, Li, Cong and Jiang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Relationship between GRFRM risk score and drug sensitivity. (A) Correlation analysis of IC50 and risk scores for GEM and chemotherapeutic agents commonly combined with GEM for LUAD. (B) Comparison of the expression levels of three prognostic genes in GEM and Cisplatin high and low IC50 groups, respectively. (C) Spearman coefficients were used for correlation analysis of drug IC50 and risk scores, as well as correlation analysis of drug IC50 and expression levels of three candidate genes. (D) Drug sensitivity of 4 FINs available for LUAD treatment was associated with GRFRM risk scores. GRFRM: GEM response and ferroptosis related model; GEM: Gemcitabine; LUAD: lung adenocarcinoma; IC50: half maximal inhibitory concentration; FINs: ferroptosis inducers. *p < 0.05; **p < 0.01; ns p > 0.05.